CLINICAL TRIALS PROFILE FOR ENSTILAR
✉ Email this page to a colleague
All Clinical Trials for ENSTILAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02858713 ↗ | Adherence in Topical Treatment of Psoriasis | Completed | Odense University Hospital | Phase 4 | 2017-01-09 | Medical adherence to topical corticosteroid products in psoriasis patients is a main determinant for poor treatment effect. The investigators aim to test if a multifaceted intervention delivered in an app (MyPso QualityCareTM owned by Leo Pharma) for smartphones combined with an Electronic Monitor (EM) (Teslo) can improve medical adherence among psoriasis patients treated with a topical calcipotriol/betamethasone dipropionate foam combination (Cal/BD) (Enstilar©). The study is classified as a phase 4 study, since it is studied if improved use of Enstilar© results in improved treatment outcomes. Link to published study protocol: https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0071-3 Link to published results from the study: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.16667 |
| NCT02881346 ↗ | Efficacy and Tolerability of Enstilar® in Daily Practice | Completed | LEO Pharma | 2016-09-01 | This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany, | |
| NCT02935582 ↗ | PSOREAL - Managing PSOriasis in the REAL World | Completed | LEO Pharma | 2017-01-01 | Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate). | |
| NCT03080545 ↗ | Enstilar in Combination With Biologic Agents | Completed | LEO Pharma | Phase 4 | 2017-05-01 | Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks. |
| NCT03080545 ↗ | Enstilar in Combination With Biologic Agents | Completed | Psoriasis Treatment Center of Central New Jersey | Phase 4 | 2017-05-01 | Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks. |
| NCT03441789 ↗ | Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis | Completed | L.H. Kircik, M.D. | Phase 4 | 2017-09-18 | This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis. Subjects will be randomized to study treatment at a 1:1 ratio of Otezla plus Enstilar foam versus Otezla plus vehicle foam. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ENSTILAR
Condition Name
Clinical Trial Locations for ENSTILAR
Trials by Country
Clinical Trial Progress for ENSTILAR
Clinical Trial Phase
Clinical Trial Sponsors for ENSTILAR
Sponsor Name
